Kidney Transplant Rejection Pipeline Review, H2 2020 - Therapeutic Analysis Report Featuring 34 Companies - ResearchAndMarkets.com

The "Kidney Transplant Rejection - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Kidney Transplant Rejection - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 9, 14, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).

• The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

• The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

• The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

• The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Key Topics Covered:

• Introduction

• Kidney Transplant Rejection - Overview

• Kidney Transplant Rejection - Therapeutics Development

• Kidney Transplant Rejection - Therapeutics Assessment

• Kidney Transplant Rejection - Companies Involved in Therapeutics Development

• Kidney Transplant Rejection - Drug Profiles

• Kidney Transplant Rejection - Dormant Projects

• Kidney Transplant Rejection - Discontinued Products

• Kidney Transplant Rejection - Product Development Milestones

• Appendix

Companies Mentioned

• Alphamab Oncology

• Amgen Inc

• Amyndas Pharmaceuticals LLC

• Astellas Pharma Inc

• Bristol-Myers Squibb Co

• Enceladus Pharmaceuticals BV

• Genzyme Corp

• Hansa Biopharma AB

• Helocyte Biosciences Inc

• Hillhurst Biopharmaceuticals Inc

• Idogen AB

• ITB-Med AB

• JN Biosciences LLC

• Junten Bio Co Ltd

• Kiniksa Pharmaceuticals Ltd

• Kronos Bio Inc

• Kyowa Kirin Co Ltd

• Lyndra Therapeutics Inc.

• Mabtech Ltd

• Medeor Therapeutics Inc

• MyeloRx LLC

• Nekonal Sarl

• NextCell Pharma AB

• Novartis AG

• OSE Immunotherapeutics

• Paranta Biosciences Ltd

• Pharmapraxis

• Rigel Pharmaceuticals Inc

• Sangamo Therapeutics Inc

• Talaris Therapeutics Inc

• TolerogenixX GmbH

• TRACT Therapeutics Inc

• Veloxis Pharmaceuticals AS

• Viela Bio Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m0y8wi

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123006066/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900